Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
50
SLGL Quote, Financials, Valuation and Earnings
Last price:
$79.30
Seasonality move
:
-0.24%
Day range:
$65.07 - $80.13
52-week range:
$4.02 - $97.97
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.85x
P/B ratio:
8.37x
Volume:
53.7K
Avg. volume:
33.6K
1-year change:
1146.18%
Market cap:
$190.9M
Revenue:
$19.4M
EPS (TTM):
-$2.20
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SLGL
Sol-Gel Technologies Ltd.
|
$900K | -$1.84 | -12.71% | -41.81% | $110.00 |
|
BLRX
BioLineRx Ltd.
|
$343K | -$1.04 | 35.2% | -49.07% | $20.33 |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -3.23% | -72.97% | $2.50 |
|
CGEN
Compugen Ltd.
|
$1.2M | -$0.08 | -46.52% | -2.83% | $5.80 |
|
PLUR
Pluri, Inc.
|
$638K | -$0.65 | 316.67% | -79.86% | $12.00 |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SLGL
Sol-Gel Technologies Ltd.
|
$68.54 | $110.00 | $190.9M | -- | $0.00 | 0% | 9.85x |
|
BLRX
BioLineRx Ltd.
|
$2.25 | $20.33 | $9.8M | -- | $0.00 | 0% | 7.74x |
|
CANF
Can-Fite BioPharma Ltd.
|
$3.01 | $2.50 | $3.9M | -- | $0.00 | 0% | 6.94x |
|
CGEN
Compugen Ltd.
|
$1.99 | $5.80 | $188.2M | 5.39x | $0.00 | 0% | 2.56x |
|
PLUR
Pluri, Inc.
|
$3.32 | $12.00 | $33.4M | -- | $0.00 | 0% | 20.28x |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
$2.61 | -- | $6.2M | -- | $0.00 | 0% | 36.87x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SLGL
Sol-Gel Technologies Ltd.
|
4.16% | 1.265 | 0.84% | 4.21x |
|
BLRX
BioLineRx Ltd.
|
35.81% | 2.584 | 59% | 1.73x |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | 1.072 | -- | -- |
|
CGEN
Compugen Ltd.
|
2.8% | 2.063 | 2.05% | 6.45x |
|
PLUR
Pluri, Inc.
|
172.93% | 0.067 | 98.32% | 0.40x |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
2.86% | 0.006 | 1.28% | 0.75x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SLGL
Sol-Gel Technologies Ltd.
|
-- | -$3.5M | -22.61% | -23.61% | -497.85% | -$7.6M |
|
BLRX
BioLineRx Ltd.
|
$91.6K | -$3.4M | -6.72% | -11.07% | -1745.49% | -$3.3M |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CGEN
Compugen Ltd.
|
$63.8M | $56M | 54.64% | 57.22% | 83.23% | -- |
|
PLUR
Pluri, Inc.
|
-$43K | -$6.5M | -93.31% | -5662.45% | -3285.86% | -$5.7M |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
-- | -$764K | -33.97% | -34.34% | -283.95% | -- |
Sol-Gel Technologies Ltd. vs. Competitors
-
Which has Higher Returns SLGL or BLRX?
BioLineRx Ltd. has a net margin of -429.17% compared to Sol-Gel Technologies Ltd.'s net margin of -1152.66%. Sol-Gel Technologies Ltd.'s return on equity of -23.61% beat BioLineRx Ltd.'s return on equity of -11.07%.
Company Gross Margin Earnings Per Share Invested Capital SLGLSol-Gel Technologies Ltd.-- -$1.07 $23.8M BLRXBioLineRx Ltd.46.93% -$0.32 $33.5M -
What do Analysts Say About SLGL or BLRX?
Sol-Gel Technologies Ltd. has a consensus price target of $110.00, signalling upside risk potential of 60.49%. On the other hand BioLineRx Ltd. has an analysts' consensus of $20.33 which suggests that it could grow by 803.7%. Given that BioLineRx Ltd. has higher upside potential than Sol-Gel Technologies Ltd., analysts believe BioLineRx Ltd. is more attractive than Sol-Gel Technologies Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SLGLSol-Gel Technologies Ltd.1 0 0 BLRXBioLineRx Ltd.2 0 0 -
Is SLGL or BLRX More Risky?
Sol-Gel Technologies Ltd. has a beta of 1.300, which suggesting that the stock is 30.014% more volatile than S&P 500. In comparison BioLineRx Ltd. has a beta of 1.309, suggesting its more volatile than the S&P 500 by 30.875%.
-
Which is a Better Dividend Stock SLGL or BLRX?
Sol-Gel Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioLineRx Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sol-Gel Technologies Ltd. pays -- of its earnings as a dividend. BioLineRx Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLGL or BLRX?
Sol-Gel Technologies Ltd. quarterly revenues are $696K, which are larger than BioLineRx Ltd. quarterly revenues of $195.2K. Sol-Gel Technologies Ltd.'s net income of -$3M is lower than BioLineRx Ltd.'s net income of -$2.3M. Notably, Sol-Gel Technologies Ltd.'s price-to-earnings ratio is -- while BioLineRx Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sol-Gel Technologies Ltd. is 9.85x versus 7.74x for BioLineRx Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLGLSol-Gel Technologies Ltd.9.85x -- $696K -$3M BLRXBioLineRx Ltd.7.74x -- $195.2K -$2.3M
-
Which has Higher Returns SLGL or CANF?
Can-Fite BioPharma Ltd. has a net margin of -429.17% compared to Sol-Gel Technologies Ltd.'s net margin of --. Sol-Gel Technologies Ltd.'s return on equity of -23.61% beat Can-Fite BioPharma Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SLGLSol-Gel Technologies Ltd.-- -$1.07 $23.8M CANFCan-Fite BioPharma Ltd.-- -- -- -
What do Analysts Say About SLGL or CANF?
Sol-Gel Technologies Ltd. has a consensus price target of $110.00, signalling upside risk potential of 60.49%. On the other hand Can-Fite BioPharma Ltd. has an analysts' consensus of $2.50 which suggests that it could grow by 1561.13%. Given that Can-Fite BioPharma Ltd. has higher upside potential than Sol-Gel Technologies Ltd., analysts believe Can-Fite BioPharma Ltd. is more attractive than Sol-Gel Technologies Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SLGLSol-Gel Technologies Ltd.1 0 0 CANFCan-Fite BioPharma Ltd.1 1 0 -
Is SLGL or CANF More Risky?
Sol-Gel Technologies Ltd. has a beta of 1.300, which suggesting that the stock is 30.014% more volatile than S&P 500. In comparison Can-Fite BioPharma Ltd. has a beta of 1.011, suggesting its more volatile than the S&P 500 by 1.09%.
-
Which is a Better Dividend Stock SLGL or CANF?
Sol-Gel Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can-Fite BioPharma Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sol-Gel Technologies Ltd. pays -- of its earnings as a dividend. Can-Fite BioPharma Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLGL or CANF?
Sol-Gel Technologies Ltd. quarterly revenues are $696K, which are larger than Can-Fite BioPharma Ltd. quarterly revenues of --. Sol-Gel Technologies Ltd.'s net income of -$3M is higher than Can-Fite BioPharma Ltd.'s net income of --. Notably, Sol-Gel Technologies Ltd.'s price-to-earnings ratio is -- while Can-Fite BioPharma Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sol-Gel Technologies Ltd. is 9.85x versus 6.94x for Can-Fite BioPharma Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLGLSol-Gel Technologies Ltd.9.85x -- $696K -$3M CANFCan-Fite BioPharma Ltd.6.94x -- -- --
-
Which has Higher Returns SLGL or CGEN?
Compugen Ltd. has a net margin of -429.17% compared to Sol-Gel Technologies Ltd.'s net margin of 84.43%. Sol-Gel Technologies Ltd.'s return on equity of -23.61% beat Compugen Ltd.'s return on equity of 57.22%.
Company Gross Margin Earnings Per Share Invested Capital SLGLSol-Gel Technologies Ltd.-- -$1.07 $23.8M CGENCompugen Ltd.94.75% $0.60 $105.7M -
What do Analysts Say About SLGL or CGEN?
Sol-Gel Technologies Ltd. has a consensus price target of $110.00, signalling upside risk potential of 60.49%. On the other hand Compugen Ltd. has an analysts' consensus of $5.80 which suggests that it could grow by 191.46%. Given that Compugen Ltd. has higher upside potential than Sol-Gel Technologies Ltd., analysts believe Compugen Ltd. is more attractive than Sol-Gel Technologies Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SLGLSol-Gel Technologies Ltd.1 0 0 CGENCompugen Ltd.5 0 0 -
Is SLGL or CGEN More Risky?
Sol-Gel Technologies Ltd. has a beta of 1.300, which suggesting that the stock is 30.014% more volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.896, suggesting its more volatile than the S&P 500 by 189.647%.
-
Which is a Better Dividend Stock SLGL or CGEN?
Sol-Gel Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sol-Gel Technologies Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLGL or CGEN?
Sol-Gel Technologies Ltd. quarterly revenues are $696K, which are smaller than Compugen Ltd. quarterly revenues of $67.3M. Sol-Gel Technologies Ltd.'s net income of -$3M is lower than Compugen Ltd.'s net income of $56.8M. Notably, Sol-Gel Technologies Ltd.'s price-to-earnings ratio is -- while Compugen Ltd.'s PE ratio is 5.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sol-Gel Technologies Ltd. is 9.85x versus 2.56x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLGLSol-Gel Technologies Ltd.9.85x -- $696K -$3M CGENCompugen Ltd.2.56x 5.39x $67.3M $56.8M
-
Which has Higher Returns SLGL or PLUR?
Pluri, Inc. has a net margin of -429.17% compared to Sol-Gel Technologies Ltd.'s net margin of -3470.71%. Sol-Gel Technologies Ltd.'s return on equity of -23.61% beat Pluri, Inc.'s return on equity of -5662.45%.
Company Gross Margin Earnings Per Share Invested Capital SLGLSol-Gel Technologies Ltd.-- -$1.07 $23.8M PLURPluri, Inc.-21.72% -$0.71 $25.4M -
What do Analysts Say About SLGL or PLUR?
Sol-Gel Technologies Ltd. has a consensus price target of $110.00, signalling upside risk potential of 60.49%. On the other hand Pluri, Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 261.45%. Given that Pluri, Inc. has higher upside potential than Sol-Gel Technologies Ltd., analysts believe Pluri, Inc. is more attractive than Sol-Gel Technologies Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SLGLSol-Gel Technologies Ltd.1 0 0 PLURPluri, Inc.1 0 0 -
Is SLGL or PLUR More Risky?
Sol-Gel Technologies Ltd. has a beta of 1.300, which suggesting that the stock is 30.014% more volatile than S&P 500. In comparison Pluri, Inc. has a beta of 0.663, suggesting its less volatile than the S&P 500 by 33.7%.
-
Which is a Better Dividend Stock SLGL or PLUR?
Sol-Gel Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sol-Gel Technologies Ltd. pays -- of its earnings as a dividend. Pluri, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLGL or PLUR?
Sol-Gel Technologies Ltd. quarterly revenues are $696K, which are larger than Pluri, Inc. quarterly revenues of $198K. Sol-Gel Technologies Ltd.'s net income of -$3M is higher than Pluri, Inc.'s net income of -$6.9M. Notably, Sol-Gel Technologies Ltd.'s price-to-earnings ratio is -- while Pluri, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sol-Gel Technologies Ltd. is 9.85x versus 20.28x for Pluri, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLGLSol-Gel Technologies Ltd.9.85x -- $696K -$3M PLURPluri, Inc.20.28x -- $198K -$6.9M
-
Which has Higher Returns SLGL or XTLB?
XTL Biopharmaceuticals Ltd. has a net margin of -429.17% compared to Sol-Gel Technologies Ltd.'s net margin of -341.36%. Sol-Gel Technologies Ltd.'s return on equity of -23.61% beat XTL Biopharmaceuticals Ltd.'s return on equity of -34.34%.
Company Gross Margin Earnings Per Share Invested Capital SLGLSol-Gel Technologies Ltd.-- -$1.07 $23.8M XTLBXTL Biopharmaceuticals Ltd.-- -$0.16 $5.9M -
What do Analysts Say About SLGL or XTLB?
Sol-Gel Technologies Ltd. has a consensus price target of $110.00, signalling upside risk potential of 60.49%. On the other hand XTL Biopharmaceuticals Ltd. has an analysts' consensus of -- which suggests that it could grow by 5048.45%. Given that XTL Biopharmaceuticals Ltd. has higher upside potential than Sol-Gel Technologies Ltd., analysts believe XTL Biopharmaceuticals Ltd. is more attractive than Sol-Gel Technologies Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SLGLSol-Gel Technologies Ltd.1 0 0 XTLBXTL Biopharmaceuticals Ltd.0 0 0 -
Is SLGL or XTLB More Risky?
Sol-Gel Technologies Ltd. has a beta of 1.300, which suggesting that the stock is 30.014% more volatile than S&P 500. In comparison XTL Biopharmaceuticals Ltd. has a beta of 1.193, suggesting its more volatile than the S&P 500 by 19.26%.
-
Which is a Better Dividend Stock SLGL or XTLB?
Sol-Gel Technologies Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XTL Biopharmaceuticals Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sol-Gel Technologies Ltd. pays -- of its earnings as a dividend. XTL Biopharmaceuticals Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLGL or XTLB?
Sol-Gel Technologies Ltd. quarterly revenues are $696K, which are larger than XTL Biopharmaceuticals Ltd. quarterly revenues of $162K. Sol-Gel Technologies Ltd.'s net income of -$3M is lower than XTL Biopharmaceuticals Ltd.'s net income of -$553K. Notably, Sol-Gel Technologies Ltd.'s price-to-earnings ratio is -- while XTL Biopharmaceuticals Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sol-Gel Technologies Ltd. is 9.85x versus 36.87x for XTL Biopharmaceuticals Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLGLSol-Gel Technologies Ltd.9.85x -- $696K -$3M XTLBXTL Biopharmaceuticals Ltd.36.87x -- $162K -$553K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
40
Is NVDA Stock a Buy?
Market Cap: $4T
P/E Ratio: 34x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 33x
Sell
26
Is GOOGL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 25x
Alerts
Sell
40
LASR alert for Mar 31
nLIGHT, Inc. [LASR] is up 5.63% over the past day.
Sell
27
SYY alert for Mar 31
Sysco Corp. [SYY] is up 2.29% over the past day.
Buy
54
NCSM alert for Mar 31
NCS Multistage Holdings, Inc. [NCSM] is down 1.71% over the past day.
